Drug Development

Taysha Gene Therapies leverages novel auto-regulatory technology and a strategic regulatory playbook to pioneer a breakthrough gene therapy for Rett syndrome.

The NHS rollout of Tryngolza offers a monthly RNA-targeted lifeline for FCS patients, proving the practical value of execution in genetic lipid disorders.

As a critical FDA decision looms for its lead drug, Hansa Biopharma partners with Cradle to build a sustainable, AI-driven autoimmune discovery engine.

Rakovina Therapeutics is teaming up with Celvion to leverage real-world AI data, aiming to bypass clinical hurdles and de-risk its ATR inhibitor pipeline.

By appointing Dr. Rajesh Chopra as CSO, Swiss biotech Numab Therapeutics signals a strategic pivot toward clinical execution for its trispecific IBD pipeline.

As GLP-1 drugs face scrutiny for causing lean tissue loss, advanced MRI biomarkers are reshaping clinical trials and the future of metabolic medicine.

Pliant Therapeutics taps veteran oncologist Dr. David Raben as CMO to steer its targeted ICI-refractory cancer program toward crucial 2027 clinical milestones.

Targeted protein degradation is breaking out of oncology. Monte Rosa’s latest Phase 1 readout tests if molecular glues can solve residual heart disease risk.

GOA Therapeutics is combining venture backing and institutional placements with retail crowdfunding as part of a $300 million strategy to fund its alcohol poisoning antidote candidate.

NuCana's new European patent for its cancer drug NUC-7738 strengthens its global IP moat, backing its clinical push against PD-1 resistant melanoma into 2029.

A new partnership between the TECPR2 Research Foundation and CDMO Forge Biologics highlights a shift: families are now acting as sophisticated biotech operators.

Invivyd's VYD2311 beats mRNA vaccines on tolerability and boosts immunity, but regulatory and economic hurdles loom large for the novel therapy.

By trading toxic payloads for precise degradation, Nurix Therapeutics is writing a masterclass in biotech survival and post-merger pharmaceutical strategy.

AstraZeneca’s $2 billion investment in Summit Therapeutics signals a structural shift in cancer care, uniting bispecifics and ADCs to dethrone incumbents.

Azurity's newly approved liquid lamotrigine isn't just a convenience—it's a critical safety measure for pediatric epilepsy and bipolar patients facing high risks.

Fueled by surging Iqirvo royalties and a new Medicare diagnostic code, GENFIT is quietly restructuring its pipeline to dominate intensive care hepatology.

Lupin’s tentative FDA approval for a liquid alternative to Eliquis highlights a strategic pivot toward value-added formulations and onshore manufacturing.

As BioAge prepares for major investor conferences, the biotech firm is nearing a critical Phase 2 readout that could redefine cardiometabolic and obesity care.

As federal research stalls, a coalition of tech and finance veterans is injecting $15 million into a nimble clinical network targeting the biological roots of Long COVID and chronic Lyme disease.

As global myopia rates surge, the FDA faces a high-stakes showdown over Sydnexis's SYD-101. The outcome will redefine pediatric eye care and supply chains.